Alcohol use disorders - clinical management: guideline consultation (17th September 2009)
A clinical practice guideline on Alcohol use disorders – clinical management is being developed for use in the NHS in England, Wales and Northern Ireland. Registered stakeholders for this guideline are invited to comment on the provisional recommendations via this website.
Closing date for consultation is 12th November 2009.
Consultation
Quitting smoking in pregnancy and following childbirth: consultation on the evidence (24th September 2009)
NICE was asked by the Department of Health (DH) to develop guidance on ‘How to stop smoking in pregnancy and following childbirth’.
All registered stakeholders are now invited to comment on the evidence that has been assembled to inform the development of this guidance. This evidence will be used by the Public Health Interventions Advisory Committee (PHIAC) to develop draft recommendations. The evidence comprises a review of effectiveness and barriers and facilitators, three expert reports and a supplementary economic analysis.
Closing date for comments is 22nd October 2009.
Consultation
A clinical practice guideline on Alcohol use disorders – clinical management is being developed for use in the NHS in England, Wales and Northern Ireland. Registered stakeholders for this guideline are invited to comment on the provisional recommendations via this website.
Closing date for consultation is 12th November 2009.
Consultation
Quitting smoking in pregnancy and following childbirth: consultation on the evidence (24th September 2009)
NICE was asked by the Department of Health (DH) to develop guidance on ‘How to stop smoking in pregnancy and following childbirth’.
All registered stakeholders are now invited to comment on the evidence that has been assembled to inform the development of this guidance. This evidence will be used by the Public Health Interventions Advisory Committee (PHIAC) to develop draft recommendations. The evidence comprises a review of effectiveness and barriers and facilitators, three expert reports and a supplementary economic analysis.
Closing date for comments is 22nd October 2009.
Consultation
Extracorporeal albumin dialysis for acute liver failure - Interventional Procedure Guidance IPG316 (23rd September 2009)
Extracorporeal albumin dialysis for acute-on-chronic liver failure involves pumping blood from the body through a thin membrane coated with albumin. Molecules that bind to the albumin membrane are then removed by passing through a charcoal column and an anion exchange, before being reintroduced into the circuit. Both water-soluble toxins (as in renal dialysis) and strongly albumin-bound toxins are removed by this process.
Albumin is purported to have important transport and detoxifications functions, such as the removal of albumin-bound substances, which may ameliorate some of the problems of liver failure.
Guidance
Sunitinib for the treatment of gastrointestinal stromal tumours - Technology Appraisal TA179 (23rd September 2009)
Sunitinib is recommended as a possible treatment for people with unresectable or metastatic malignant gastrointestinal stromal tumours if they have already tried imatinib treatment but it has not worked or was not suitable. The manufacturer of sunitinib has agreed to cover the cost of the drug for the first treatment cycle.
Treatment should be supervised by a specialist who is experienced in treating people with gastrointestinal stromal tumours.
Guidance
Hysteroscopic sterilisation by tubal cannulation and placement of intrafallopian implants - Interventional Procedure Guidance IPG315 (23rd September 2009)
Sterilisation results in the inability to conceive children naturally. It is sometimes chosen as a method of birth control and is usually permanent. In women, hysteroscopic sterilisation by tubal cannulation and placement of intrafallopian implants is used to block the fallopian tubes, with the aim of preventing the eggs from reaching the womb and becoming fertilised. The procedure is performed by passing a small camera and tube (hysteroscope) through the vagina and cervix. A very small implant called a microinsert is placed into each fallopian tube using specialised narrow surgical instruments that are passed through the hysteroscope. The presence of the microinserts causes scar tissue to form in the fallopian tubes, which eventually blocks them.
Guidance
Individually magnetic resonance imaging - designed unicompartmental interpositional implant insertion for osteoarthritis of the knee - Interventional Procedure Guidance IPG317 (23rd September 2009)
Osteoarthritis of the knee can cause pain, stiffness, swelling and difficulty in walking. In this procedure, an individually designed implant is inserted at the knee between the thigh and shin bones with the object of realigning the knee and preventing bone-on-bone rubbing. This aims to reduce pain and delay the progression of osteoarthritis and the need for further, more invasive surgery, such as knee replacement.
Guidance
Pemetrexed for the first-line treatment of non-small-cell lung cancer - Technology Appraisal TA181 (23rd September 2009)
Pemetrexed is recommended as a possible treatment for locally advanced or metastatic non-small-cell lung cancer (NSCLC) if:
Guidance
Ustekinumab for the treatment of adults with moderate to severe psoriasis - Technology Appraisal TA180 (23rd September 2009)
Ustekinumab is recommended as a possible treatment for people with plaque psoriasis if:
Guidance on differences in the uptake of immunisations (including targeted vaccines) in people younger than 19 years - Public Health Guidance PH21 (23rd September 2009)
This guidance is for NHS and other professionals responsible for the immunisation of children and young people. They may work in: children’s services, local authorities, education and the wider public, private, voluntary and community sectors. It may also be of interest to parents.
The guidance aims to increase immunisation uptake among those aged under 19 years from groups where uptake is low. It also aims to ensure babies born to mothers infected with hepatitis B are immunised.
Guidance
Promoting young people's social and emotional wellbeing in secondary education - Public Health Guidance PH20 (23rd September 2009)
This guidance is for all those who have a responsibility for the social and emotional wellbeing of young people in secondary education. This includes teachers, support staff, governors and professionals with public health as part of their remit working in education (including the independent sector), local authorities, the NHS and the wider public, voluntary and community sectors.
It focuses on interventions to support all young people aged 11-19 who attend any education establishment.
Guidance
Extracorporeal albumin dialysis for acute-on-chronic liver failure involves pumping blood from the body through a thin membrane coated with albumin. Molecules that bind to the albumin membrane are then removed by passing through a charcoal column and an anion exchange, before being reintroduced into the circuit. Both water-soluble toxins (as in renal dialysis) and strongly albumin-bound toxins are removed by this process.
Albumin is purported to have important transport and detoxifications functions, such as the removal of albumin-bound substances, which may ameliorate some of the problems of liver failure.
Guidance
Sunitinib for the treatment of gastrointestinal stromal tumours - Technology Appraisal TA179 (23rd September 2009)
Sunitinib is recommended as a possible treatment for people with unresectable or metastatic malignant gastrointestinal stromal tumours if they have already tried imatinib treatment but it has not worked or was not suitable. The manufacturer of sunitinib has agreed to cover the cost of the drug for the first treatment cycle.
Treatment should be supervised by a specialist who is experienced in treating people with gastrointestinal stromal tumours.
Guidance
Hysteroscopic sterilisation by tubal cannulation and placement of intrafallopian implants - Interventional Procedure Guidance IPG315 (23rd September 2009)
Sterilisation results in the inability to conceive children naturally. It is sometimes chosen as a method of birth control and is usually permanent. In women, hysteroscopic sterilisation by tubal cannulation and placement of intrafallopian implants is used to block the fallopian tubes, with the aim of preventing the eggs from reaching the womb and becoming fertilised. The procedure is performed by passing a small camera and tube (hysteroscope) through the vagina and cervix. A very small implant called a microinsert is placed into each fallopian tube using specialised narrow surgical instruments that are passed through the hysteroscope. The presence of the microinserts causes scar tissue to form in the fallopian tubes, which eventually blocks them.
Guidance
Individually magnetic resonance imaging - designed unicompartmental interpositional implant insertion for osteoarthritis of the knee - Interventional Procedure Guidance IPG317 (23rd September 2009)
Osteoarthritis of the knee can cause pain, stiffness, swelling and difficulty in walking. In this procedure, an individually designed implant is inserted at the knee between the thigh and shin bones with the object of realigning the knee and preventing bone-on-bone rubbing. This aims to reduce pain and delay the progression of osteoarthritis and the need for further, more invasive surgery, such as knee replacement.
Guidance
Pemetrexed for the first-line treatment of non-small-cell lung cancer - Technology Appraisal TA181 (23rd September 2009)
Pemetrexed is recommended as a possible treatment for locally advanced or metastatic non-small-cell lung cancer (NSCLC) if:
- the cancer is a particular type (adenocarcinoma or large-cell carcinoma) and
- the person has not had any treatment for NSCLC before.
Guidance
Ustekinumab for the treatment of adults with moderate to severe psoriasis - Technology Appraisal TA180 (23rd September 2009)
Ustekinumab is recommended as a possible treatment for people with plaque psoriasis if:
- standard assessments show that their psoriasis is severe and is affecting their quality of life and
- their psoriasis has not improved with other treatments such as ciclosporin, methotrexate or PUVA (psoralen and long-wave ultraviolet radiation), or they have had side effects with these treatments in the past or there is a medical reason why they should not be given them.
Guidance on differences in the uptake of immunisations (including targeted vaccines) in people younger than 19 years - Public Health Guidance PH21 (23rd September 2009)
This guidance is for NHS and other professionals responsible for the immunisation of children and young people. They may work in: children’s services, local authorities, education and the wider public, private, voluntary and community sectors. It may also be of interest to parents.
The guidance aims to increase immunisation uptake among those aged under 19 years from groups where uptake is low. It also aims to ensure babies born to mothers infected with hepatitis B are immunised.
Guidance
Promoting young people's social and emotional wellbeing in secondary education - Public Health Guidance PH20 (23rd September 2009)
This guidance is for all those who have a responsibility for the social and emotional wellbeing of young people in secondary education. This includes teachers, support staff, governors and professionals with public health as part of their remit working in education (including the independent sector), local authorities, the NHS and the wider public, voluntary and community sectors.
It focuses on interventions to support all young people aged 11-19 who attend any education establishment.
Guidance
No comments:
Post a Comment